Missed Opportunities for Preexposure Prophylaxis Initiation in Hospitalized Persons With Opioid Use Disorder and Infectious Diseases.

Autor: Parchinski K; Section of Infectious Diseases, Department of Internal Medicine, AIDS Program, Yale School of Medicine, New Haven, Connecticut, USA.; Medical School, Medical College of Georgia, Augusta, Georgia, USA., Neirinckx V; Section of Infectious Diseases, Department of Internal Medicine, AIDS Program, Yale School of Medicine, New Haven, Connecticut, USA., Frank C; Section of Infectious Diseases, Department of Internal Medicine, AIDS Program, Yale School of Medicine, New Haven, Connecticut, USA., Di Paola A; Section of Infectious Diseases, Department of Internal Medicine, AIDS Program, Yale School of Medicine, New Haven, Connecticut, USA.; Center for Interdisciplinary Research on AIDS, Yale University School of Public Health, New Haven, Connecticut, USA., Tarfa A; Section of Infectious Diseases, Department of Internal Medicine, AIDS Program, Yale School of Medicine, New Haven, Connecticut, USA.; Center for Interdisciplinary Research on AIDS, Yale University School of Public Health, New Haven, Connecticut, USA., Shenoi S; Section of Infectious Diseases, Department of Internal Medicine, AIDS Program, Yale School of Medicine, New Haven, Connecticut, USA.; Center for Interdisciplinary Research on AIDS, Yale University School of Public Health, New Haven, Connecticut, USA., Vander Wyk B; Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA., Roth P; Department of Medicine, Prisma Health Addiction Medicine Center, Greenville, South Carolina, USA.; Department of Medicine, University of South Carolina School of Medicine, Greenville, South Carolina, USA., Ghantous T; Section of Infectious Diseases, Department of Internal Medicine, AIDS Program, Yale School of Medicine, New Haven, Connecticut, USA., Wegman MK; Section of Infectious Diseases, Department of Internal Medicine, AIDS Program, Yale School of Medicine, New Haven, Connecticut, USA., Strong M; Department of Medicine, Prisma Health Addiction Medicine Center, Greenville, South Carolina, USA.; Department of Medicine, University of South Carolina School of Medicine, Greenville, South Carolina, USA., Levin FR; Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York City, New York, USA.; Department of Psychiatry, New York State Psychiatric Institute, New York City, New York, USA., Brady K; Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, USA., Nunes E; Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York City, New York, USA.; Department of Psychiatry, New York State Psychiatric Institute, New York City, New York, USA., Litwin AH; Department of Medicine, Prisma Health Addiction Medicine Center, Greenville, South Carolina, USA.; Department of Medicine, University of South Carolina School of Medicine, Greenville, South Carolina, USA., Springer SA; Section of Infectious Diseases, Department of Internal Medicine, AIDS Program, Yale School of Medicine, New Haven, Connecticut, USA.; Center for Interdisciplinary Research on AIDS, Yale University School of Public Health, New Haven, Connecticut, USA.
Jazyk: angličtina
Zdroj: Open forum infectious diseases [Open Forum Infect Dis] 2024 Jul 10; Vol. 11 (7), pp. ofae366. Date of Electronic Publication: 2024 Jul 10 (Print Publication: 2024).
DOI: 10.1093/ofid/ofae366
Abstrakt: Hospitalizations are increasing among persons who use opioids, secondary to overdose and infections. Our study identified acute hospitalization as a reachable moment for engaging people who use drugs in increased screening and education about human immunodeficiency virus risk and prevention (preexposure prophylaxis).
Competing Interests: Potential conflicts of interest. S. A. S. has provided paid scientific consultation to Alkermes Inc and has received in-kind study drug donations from Alkermes Inc and Indivior Pharmaceutical Company for National Institutes of Health (NIH)–funded research. Sublocade was donated in-kind by Indivior Inc after an investigator-initiated application was approved. F. R. L. receives grant support from the NIDA, NCATS, Substance Abuse and Mental Health Services Administration, US World Meds; receives research support from Aelis Pharmaceuticals; receives medication from Indivior for research; receives royalties from APA Publishing; served as an unpaid member of a scientific advisory board for Alkermes, Indivior, Novartis, Teva, and US WorldMeds; and is a consultant to Major League Baseball. S. S.’s spouse worked for Merck pharmaceuticals from 1997 to 2007 and retains company stock in his retirement account. There is no conflict of interest, but it is included in the interest of full disclosure. K. B. receives grant support from NIDA, NCATS, and the Duke Foundation. A. H. L. has served on advisory boards for Gilead Sciences and Merck Pharmaceuticals and received research funding from Gilead Sciences. E. N. has served as an investigator on NIH-funded studies that received donated medication or digital therapeutics from Alkermes, Braeburn, Camurus, Indivior, Chess Health, and Pear Therapeutics, and has served as a consultant without compensation to Alkermes, Camurus, Indivior, and Pear Therapeutics. All other authors report no potential conflicts.
(© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje